HIVNET012 randomized trial. Lancet 1999; 354: 795-802.

- 2. Edward MC, Rhoda SS, Richard G, Pavel K, Gwendolyn S, Mary JO, *et al.* Reduction of maternalinfant transmission of Human immunodeficiency virus type 1 with Zidovudine treatment. PACTG076. N Engl J Med 1994; 331: 1173-1180.
- 3. Marc L, Gonzagne J, Sophie LC, Jean YM, Nicole NGH, Suporn K, *et al.* Single dose perinatal Nevirapine plus standard Zidovudine to prevent Mother-to-child transmission of HIV-1 in Thailand. N Engl J Med 2004; 351: 217-228.
- Cooper ER, Charurat M, Mofenson L, Hanson IC, Pitt J, Diaz C, *et al.* Combination antiretroviral strategies for the treatment of pregnant HIV-1 infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr Hum Retroviral 2002; 29: 484-494.
- 5. WHO PMTCT guidelines 2006 revision. Antiretroviral drugs for treating pregnant women and preventing HIV infection in infants in resource limited settings. Recommendations for a public health approach. Available from: URL: http:// www.who.int/hiv/mediacentre/fs_2006 guidelines pmtct/en/index.html. Accessed June 20, 2006.

Tuberculosis Infection in BCG Vaccinated Children

- A good number of BCG vaccinated children do not develop a scar. In Kerala, BCG coverage is above 95%. But in the present study(1), only 59% of children have a BCG scar. This clearly shows that the BCG scar alone, to identify the vaccinated children, is an irrational and misleading criteria. This study ideally should have been conducted as a prospective study(2,3).
- 2. Tuberculin induration measured, should be interpreted without any prejudice, whether the children are vaccinated or not. But this study probably brings out that the interpretation of Tuberculin induration differentially in vaccinated and unvaccinated children is baseless.

V M Kartha,

Consultant Pediatrician, Geepee Clinic, Perumbavoor, Kerala, India. E-mail: dr.v.m.kartha@sify.com

REFERENCES

1. Pulickal AS, Fernandez GVJ. Comparison of the Prevalence of Tuberculosis Infection in BCG Vaccinated versus Non-Vaccinated School Age Children. Indian Pediatr 2007; 44: 344-347.

- 2. Nutrition Subcommittee of the Indian Academy of Pediatrics. Classification of Protein Energy Malnutrition. Indian Pediatr 1972; 9:360.
- 3. Singh MC, Badole CM, Singh MP. Immunization coverage and the knowledge and practice of mothers regarding immunization in rural area. Indian J Public Health.1994; 38:103-107.

Reply

- We disagree. Studies have demonstrated >90% scar formation post-vaccination with BCG(1-5). These data indicate that a BCG scar is indeed a sensitive and reliable indicator of BCG vaccination. However, we do concur with Dr. Kartha that a prospective study could have had more validity but temporal and resource limitations ruled this out.
- 2. We do not deny that the use of a differential cutoff is unconventional. The multiple reasons for using this strategy have been described in detail in the article. Our hypothesis is that, despite tuberculin reactions appearing similar in both groups (as suggested by the data and pointed out by Dr. Kartha), vaccinated and unvaccinated children, ipso facto, have different risks of acquiring tuberculosis and developing disseminated disease that necessitates a different tuberculin cut-off reading for each group. It is an

extension of the same logic that dictates >5mm being considered a positive reaction in an HIV infected individual.

Anoop S Pulickal,

Department of Paediatrics, John Radcliffe Hospital, Oxford OX3 9DU, UK. E-mail: anoop.sebastian@paediatrics.ox.ac.uk

REFERENCES

- Sedaghatian MR, Shana'a IA. Evaluation of BCG at birth in the United Arab Emirates. Tubercle 1990; 71: 177-180.
- 2. Jeena PM, Chhagan MK, Topley J, Coovadia HM.

Safety of the intradermal Copenhagen 1331 BCG vaccine in neonates in Durban, South Africa. Bull World Health Organ 2001; 79: 337-343.

- 3. Karalliede S, Katugaha LP, Uragoda CG. Tuberculin response of Sri Lankan children after BCG vaccination at birth. Tubercle 1987; 68: 33-38.
- 4. Santiago EM, Lawson E, Gillenwater K, Kalangi S, Lescano AG, Du Quella G, et al. A prospective study of bacillus Calmette-Guérin scar formation and tuberculin skin test reactivity in infants in Lima, Peru. Pediatrics 2003; 112: 298.
- Rani SH, Vijayalakshmi V, Sunil K, Lakshmi KA, Suman LG, Murthy KJ. Cell mediated immunity in children with scar-failure following BCG vaccination. Indian Pediatr 1998; 35: 123-127.

Usefulness of dTPa

What new information is provided by a multicentric Indian study which concludes that dTPa (Boostrix) is safe and well-tolerated at age 4-6 years?(1) It is well known that DTP is safe and well tolerated at this age. Reducing the dose of diphtheria toxoid and replacing whole cell pertussis vaccine (Pw) by acellular pertussis vaccine (Pa) is not going to make it unsafe or less tolerable to children.

The IAP Immunization Schedule recommends the use of DTP at 4-6 years of age while the GOI Schedule recommends DT; no international immunization schedule recommends low-dose diphtheria toxoid (2 Lf) at this age. So the pertinent point is whether a vaccine that contains low-dose diphtheria toxoid is effective against diphtheria when administered at this age. Antibody levels to diphtheria toxoid are known to correlate with efficacy; unfortunately the study does not mention antibody levels before and after the administration of dTPa. Until this information is available, it is unethical to use this vaccine as a booster at 4-6 years of age.

Newton Luiz,

Dhanya Mission Hospital, Potta PO, Thrissur, Kerala 680 722, India. E-mail: newtonluiz@gmail.com

REFERENCES

- Bose A. Dubey AP, Gandhi D, Pandit A, Raghu MB, Raghupathy P, *et al.* Safety and Reactogenecity of a low-dose diphtheria-tetanus-acellular pertussis vaccine (BoostrixTM) in pre-school Indian children. Indian Pediatr 2007; 44: 421-424.
- Bavdekar SB, Maiya PP, Subba Rao SD, Datta SK, Bock HL. Immunogenicity and safety of combined diphtheria-tetanus-whole cell pertussis-hepatitis B/ hemophilus influenzae type b vaccine in Indian infants. Indian Pediatr 2007; 44: 505-510.